The core focus of C-Dots, LLC as a company is the development and implementation of safer and cost-effective nano drug delivery models for oncology, bone diseases, and neurodegenerative diseases such as Alzheimer’s Disease (a main priority). Our researchers are vigilantly developing target-specific drug delivery systems using biocompatible nanoparticle carbon dots (c-dots). Unlike chemotherapy, nano drug delivery systems based on c-dots potentially reduce the acute toxicity towards the healthy cells, while enhancing the drug efficacy with lower dosages.
C-Dots, LLC is a Florida Limited Liability Company organized in January 2017. The company is based upon the work of Professor Roger LeBlanc, PhD and was co-founded with Edward D. Miller, Chief Executive Officer.
Extensive intellectual property patents have been filed in the U.S. and internationally, beginning in 2015.
Funding for research has thus far been provided by grants from the National Science Foundation (NSF) and the National Institutes of Health (NIH), with private investments into C-Dots, LLC made by Huston Labs, LLC and other individual investors.
